StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — ICICI Securities

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byICICI SecuritiesHorizon: NA (inferred 1 year)4 Sept 2026via Institutional / Brokerage Research

Entry₹1,927.6Inferred
Target₹2,305
Total upside +19.58%
Stop lossNot given
CMP₹1,782.61h ago
Active-7.52%+29.31%upside left 11 mo left
Follow ICICI Securities for new calls(67% target hit, 1026 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 5 other Long-term calls on EMCURESee 211 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:37 pm IST
18 supporting7 neutral3 opposing
Supports the BUY call (18)

Emcure Pharma Shares May Rally Up To 33%, Says MOFSL On Strong Growth Outlook; Check Target Price

NewsNdtv-Profit·22 Oct · today

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·21 Oct · yesterday

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·21 Oct · yesterday

Emcure Pharmaceuticals Limited (NSE: EMCURE) Reveals Strong Revenue Growth in FY26 Presentation

NewsGoogle News·28 Sept · 3w ago

(opens in new tab)

Emcure Pharmaceuticals reports over $1 billion operating revenue in FY26 with 16.6% growth

NewsGoogle News·25 Sept · 4w ago

(opens in new tab)
Neutral / worth noting (7)

Q2 FY27 results scheduled — board meets 03 Nov 2026

BSE · Board Meeting·In 11 days

(opens in new tab)

Emcure Pharmaceuticals has proposed a scheme of amalgamation for its wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, into the parent company.

BSE · Company Update·12 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (3)

Emcure Pharmaceuticals received income tax orders imposing an aggregate penalty of approximately Rs 57.74 crore for the financial years 2014-15 to 2020-21. The company is evaluating legal remedies.

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·2 Oct · 3w ago

(opens in new tab)

Emcure Pharmaceuticals has received income tax orders imposing an aggregate penalty of approximately Rs 57.74 crore for the financial years 2014-15 to 2020-21. The company intends to appeal the orders

BSE · Company Update·2 Oct · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from ICICI Securities

Every call and its outcome